Clinical trials in Harderwijk

63 clinical trials in Harderwijk, The Netherlands. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Harderwijk at a glance

clinical trials

Paediatric trials0
Research sites0

Quick filters

63 trials in Harderwijk

Open in trial search

Non-small cell lung cancer stage I

Recruiting

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:MRNA-4157
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Small cell lung cancer

Recruiting

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Topotecan Hydrochloride
Sponsor:Zai Lab (US) LLC

Contact Research Centre

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Recruiting

Registered drug

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Baxdrostat
Sponsor:AstraZeneca AB

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Eli Lilly & Co.

Contact Research Centre

Neoplasm

Recruiting

Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

Registered drugNo placebo

Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Adagrasib
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Lipoprotein (a) increased

Recruiting

Phase 2 study of MK-7262 and enlicitide decanoate in adults with high lipoprotein(a)

Investigational

Phase 2 study of MK-7262 and enlicitide decanoate in adults with high lipoprotein(a)

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Arteriosclerosis

Recruiting

Effect of Lepodisiran on Coronary Plaque in Adults with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease or High Risk for First Event

Investigational

Effect of Lepodisiran on Coronary Plaque in Adults with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease or High Risk for First Event

Investigational

The Netherlands

Participants:18–64 years
Substances:LY3819469 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Chronic lymphocytic leukaemia+2

Recruiting

Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Venetoclax
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Amgen Inc.

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Axial spondyloarthritis+3

Recruiting

Study of Janus kinase inhibitor dose reduction in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis who have achieved low disease activity

Registered drugNo placebo

Study of Janus kinase inhibitor dose reduction in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis who have achieved low disease activity

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Baricitinib
Sponsor:Sint Maartenskliniek Stichting

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Harderwijk

What the registry says about research in the country

01 Oncology - Lung Cancer

Multiple innovative trials focusing on non-small cell lung cancer (NSCLC) treatments, evaluating new therapeutic combinations and targeted approaches for different disease stages.

Advanced and Metastatic NSCLC
Early-Stage Treatment
Targeted Therapies

Studies are investigating novel drug combinations and immunotherapy approaches to improve patient outcomes.

02 Hematologic Malignancies

Groundbreaking research in chronic lymphocytic leukemia (CLL) and lymphomas, exploring various treatment combinations and duration-optimized approaches.

First-line CLL Treatments
Novel Drug Combinations
Treatment Duration Studies

Focus on personalized treatment strategies and improved patient outcomes through innovative therapies.

03 Cardiovascular Research

Studies addressing atherosclerotic cardiovascular disease and heart failure prevention, testing new therapeutic approaches and preventive strategies.

Heart Failure Prevention
Cardiovascular Risk Management
Novel Therapeutic Agents

Emphasis on reducing major adverse cardiovascular events and improving patient outcomes.

Back to the Netherlands All countries